MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement for Afrezza with Tanner Pharma Group, a global provider of integrated specialty access solutions. The agreement names Tanner as a distributor of Afrezza outside of the United States in regions the product is not yet registered. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

“Al Mann had a vision of making Afrezza available to all people living with diabetes around the world and this agreement helps accelerate that access to Afrezza on a named patient access basis in underserved international markets,” said Michael Castagna, Chief Executive Officer of MannKind. “Our partnership with Tanner Pharma to distribute Afrezza provides us a strong partner with a track record of success in working with physicians, hospitals and ministries of health to provide medicine that is not currently available in their country.”

The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group.

“We are pleased to partner with MannKind in helping fulfill the demand for Afrezza in countries outside the U.S.,” said Banks Bourne, Chairman and Founder of Tanner Pharma Group.